Evidence map›Paper›PMID 42334179›Full record

ArticleMolecular imaging and radionuclide therapy2026

Follicular Thyroid Carcinoma with Cavernous Sinus Metastasis and Perineural Spread: A Rare Manifestation of Radioiodine-refractory Disease.

Mohd Fazrin Mohd Rohani, Hamidah Lau, Jasmin Jalil, Razmin Ghazali, Siti Zarina Amir Hassan

Abstract read
In one paragraph

Article in Molecular imaging and radionuclide therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Mohd Fazrin Mohd RohaniHospital Kuala Lumpur, Clinic of Nuclear Medicine, Kuala Lumpur, Malaysia.ORCID 0000-0002-8450-0170
Hamidah LauHospital Kuala Lumpur, Clinic of Nuclear Medicine, Kuala Lumpur, Malaysia.ORCID 0009-0007-7492-0423
Jasmin JalilPusat Kanser Tun Abdullah Ahmad Badawi, Universiti Sains Malaysia, Kepala Batas, Department of Biomedical Imaging, Pulau Pinang, Malaysia.ORCID 0000-0002-3528-5988
Razmin GhazaliHospital Kuala Lumpur, Clinic of Pathology, Kuala Lumpur, Malaysia.ORCID 0009-0008-9429-9926
Siti Zarina Amir HassanHospital Kuala Lumpur, Clinic of Nuclear Medicine, Kuala Lumpur, Malaysia.ORCID 0000-0002-7421-3530

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cavernous sinus metastasis from follicular thyroid carcinoma (FTC) is exceedingly rare and typically indicates advanced, radioiodine-refractory disease. We report a 37-year-old man with minimally invasive FTC who was treated with total thyroidectomy, neck dissection, and cumulative radioiodine therapy totaling 720 mCi for persistent iodine-avid disease. Four years later, he developed progressive left-sided palsies of cranial nerves III, IV, and VI. Imaging revealed a cavernous sinus mass with orbital apex extension and perineural spread. Serum thyroglobulin was markedly elevated (>500 ng/mL), whereas diagnostic radioiodine scintigraphy demonstrated no uptake, a finding consistent with dedifferentiated disease. Biopsy confirmed metastatic FTC. The patient received external beam radiotherapy and systemic therapy with lenvatinib; however, the disease progressed, and he died 16 months after the diagnosis of cavernous sinus metastasis. This case highlights the aggressive potential of FTC, the limitations of radioiodine imaging in dedifferentiated disease, and the poor prognosis associated with skull-base metastases despite multimodal therapy.

Indexed as

18F-FDG PET/CTcavernous sinus metastasisFollicular thyroid canceriodine-131 whole-body scintigraphy

Identifiers

PMID42334179
PMCPMC13640851

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.